In sum, a patient-centred approach should guide the selection of SGLT2 inhibitors for patients with and without T2D to improve cardiovascular and kidney outcomes, irrespective of HbA1c. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.